Loading...
Small trials and a meta-analysis have suggested that intensive- versus moderate-dose statin therapy is associated with elevated risk for developing insulin resistance and type 2 diabetes (JW Gen Med Mar 4 2010). Researchers explored this association in a meta-analysis of five randomized statin trials with nearly 33,000 participants who did not have diabetes at baseline.
During a mean follow-up of 4.9 years, 8.4% of participants developed diabetes, and 20.4% experienced major adverse cardiovascular (CV) events. Intensive-dose therapy (daily atorvastatin [Lipitor; 80 mg] or simvastatin [80 mg]) was compared with moderate-dose therapy (daily atorvastatin [10 mg], simvastatin [20 mg], or pravastatin [40 mg]). Risk for diabetes was higher by 12% …